Form 4: ImmunityBio CEO Adcock's Latest Stock Transactions

ImmunityBio CEO Richard Adcock reported the vesting of 152,439 restricted stock units and the subsequent sale of 77,560 shares for tax purposes.

Summary

• Richard Adcock, CEO & President and Director of ImmunityBio, Inc. (IBRX), reported transactions involving company stock.
• On February 22, 2026, 152,439 Restricted Stock Units (RSUs) vested, converting into an equal number of common shares.
• Concurrently, 77,560 shares of common stock were disposed of to cover tax obligations related to the RSU vesting, at a price of $8.7 per share.
• Following these transactions, Adcock beneficially owns 560,344 shares of ImmunityBio common stock.
• An additional 152,439 Restricted Stock Units remain beneficially owned, representing the final tranche of an RSU award set to vest on February 22, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and tax planning, with the CEO maintaining a significant equity position.

Positives

• The vesting of 152,439 Restricted Stock Units indicates a scheduled compensation event for the CEO, aligning management's interests with shareholder value.
• The CEO retains a significant stake of 560,344 common shares after the transactions, demonstrating continued commitment to the company.

Negatives

• A portion of the vested shares (77,560 shares) was sold to cover tax liabilities, which is a common practice but reduces the CEO's direct shareholding.

Future Outlook

The filing indicates a future vesting event for 152,439 Restricted Stock Units on February 22, 2027, contingent on the reporting person's continued service.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving executive compensation like RSU vesting, are routine events in the biotechnology sector. While the sale of shares for tax purposes is common, the retention of a substantial equity stake by the CEO is generally viewed positively by the market as it aligns executive incentives with long-term company performance.

Comparison to Industry Standards

• The RSU vesting and subsequent tax-related sale are standard practices for executive compensation in publicly traded companies, particularly within the biotech industry.
• Many executives in comparable biotech firms, such as Moderna (MRNA) or BioNTech (BNTX), frequently report similar Form 4 transactions as their equity awards vest.
• The specific withholding percentage for taxes (77,560 out of 152,439 vested shares, approximately 50.8%) is typical for high-income earners subject to federal and state income taxes on equity compensation.

Stakeholder Impact

• Shareholders: The CEO's continued significant ownership stake may be seen as a positive signal of alignment with shareholder interests. The sale for tax purposes is a routine event and not indicative of a lack of confidence.
• Employees: The RSU vesting demonstrates the company's executive compensation structure, which can influence employee morale and retention strategies.

Next Steps

• The remaining 152,439 Restricted Stock Units are scheduled to vest on February 22, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The CEO maintains a substantial equity position, which is generally a positive sign of alignment, but the transaction itself is expected and does not alter the investment thesis.

Keywords

ImmunityBio, IBRX, Richard Adcock, SEC Form 4, Insider Trading, Stock Transactions, Restricted Stock Units, RSU Vesting, CEO Stock, Beneficial Ownership